ClinicalTrials.gg
Sign In
Not yet recruitingNCT07743229CogSCCUpdated Nov 4, 2026

COG+OT Telerehabilitation for Adults With Subjective Cognitive Complaints

An interventional study of COG+OT Telerehabilitation in Subjective Cognitive Complaints, Ehlers-Danlos Syndrome and Cognitive Dysfunction, sponsored by Medical University of South Carolina. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Treatment

Updated Nov 4, 2026Start date movedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Study summary

This pilot study will evaluate a comprehensive cognitive assessment approach and personalized neurocognitive telerehabilitation intervention for adults with subjective cognitive complaints (SCC). The study includes older adults with SCC and adults with Ehlers-Danlos Syndrome (EDS) and SCC. Participants will complete pre- and post-treatment assessments and receive a 6-week COG+OT telerehabilitation intervention that combines cognitive rehabilitation and occupational therapy strategies to support everyday functional cognition.

02

Conditions studied

  • Subjective Cognitive Complaints
  • Ehlers-Danlos Syndrome
  • Cognitive Dysfunction

Keywords

  • Subjective cognitive complaints
  • Brain fog
  • Functional cognition
  • Occupational therapy
  • Cognitive rehabilitation
  • Ehlers-Danlos Syndrome
03

In context

Ehlers-Danlos Syndrome

66 studies on the registry are indexed under Ehlers-Danlos Syndrome; 24 are open to participants now.

This study's planned enrollment of 16 is below the median of 60 across 32 interventional studies indexed under Ehlers-Danlos Syndrome.

Browse Ehlers-Danlos Syndrome studies →

Lead sponsor

Medical University of South Carolina is the lead sponsor of 874 studies on the registry; 166 are open to participants now.

Of its 131 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.

Browse Medical University of South Carolina studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Endorsement of subjective cognitive complaints as indicated by a score ≥4 on the Healthy Brain 9 (HB9)
  • Community-dwelling adult aged 60 years or older, or adult aged 21 years or older with a diagnosis of Ehlers-Danlos Syndrome (EDS)
  • English as the primary language
  • Access to and ability to use a smartphone compatible with the NeuroUX platform
  • Access to a device capable of supporting a telerehabilitation visit, such as a phone, tablet, or laptop, and a reliable Wi-Fi or cellular internet connection
  • Able to participate in study assessment sessions as determined by the licensed, experienced telerehabilitation occupational therapist

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of dementia or mild cognitive impairment
  • Significant or unstable conditions or treatments for medical conditions that may impact cognition, such as traumatic brain injury or brain tumor
  • Inability to engage in study-related procedures as determined by the study team
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Adults With Subjective Cognitive Complaints

    Community-dwelling adults aged 60 years or older or Adult with Elhers Danlos Syndrome with subjective cognitive complaints who receive the 6-week COG+OT telerehabilitation intervention and complete pre- and post-treatment cognitive and functional assessments.

    Behavioral: COG+OT Telerehabilitation

Interventions

  • BehavioralCOG+OT Telerehabilitation

    COG+OT is a personalized telerehabilitation program that combines cognitive rehabilitation and occupational therapy. Cognitive rehabilitation sessions focus on strategies for attention, memory, organization, planning, problem solving, and executive function. Occupational therapy sessions use meaningful daily activities to support application and generalization of cognitive strategies in home- and community-based tasks. The intervention is delivered remotely over 6 weeks in 10 sessions lasting approximately 45 to 60 minutes each.

06

What researchers measure

Primary outcomes

  1. Change in Everyday Cognition Scale-II (ECog-II) Score

    Change in subjective cognition measured using the Everyday Cognition Scale-II (ECog-II), a self-report measure assessing perceived cognitive functioning across everyday activities, including memory, executive function, language, and attention.

    Time frame: Pre-treatment to post-treatment, approximately 8 weeks

Secondary outcomes

  1. Retention Rate

    Feasibility measured as the percentage of participants who complete all study sessions.

    Time frame: Through study completion, approximately 8 weeks

  2. Adherence Rate

    Feasibility measured as the percentage of participants completing intervention activities for each session, including functional task practice and homework.

    Time frame: Through study completion, approximately 8 weeks

07

Study locations

2 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Jul 2027, 8 months later.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2026
First posted
Aug 3, 2026
StartEst.
Nov 1, 2026was Oct 2026
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Nov 1, 2026
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Start date Oct 1, 2026→Nov 1, 2026
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07743229
Lead sponsor
Medical University of South Carolina
Responsible party
Sponsor
First posted
Aug 3, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Patricia Finetto, OTR/L
Contact
piersonp@musc.edu
843-792-8533
Michelle Woodbury, PhD, OTR/L
Contact
woodbuml@musc.edu
Michelle Woodbury, PhD, OTR/L
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Ehlers-Danlos Syndrome →

Other studies from this sponsor

Medical University of South Carolina →

Start the discussion